Paraganglioma: all 108 studies
Page 1 of 2. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck ParagangliomasNot yet recruitingNCT07784595Not applicable
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingNCT07743138Phase 2
- Zanzalintinib in Unresectable and Progressive MPGGsNot yet recruitingNCT07714551Phase 2
- An Experimental Study of Belzutifan Impact on Catecholamine MetabolismRecruitingNCT07680205Phase 2
- 211At-MABG in Adults With Advanced Neuroendocrine CancersNot yet recruitingNCT07661420Phase 1
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
- Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)Not yet recruitingNCT07538791
- Prospective Cohort Study of Pheochromocytoma/ParagangliomaNot yet recruitingNCT07516275
- Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and ParagangliomasEnrolling by invitationNCT07316075
- Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and ParagangliomaRecruitingNCT07288931Not applicable
- Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaRecruitingNCT07282587Phase 2
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaRecruitingNCT07195500
- Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal TumorsEnrolling by invitationNCT07182175
- Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialRecruitingNCT07167329Phase 2
- National Study of Adrenal TumoursEnrolling by invitationNCT06870396
- Ivonescimab in the Treatment of Multiple Advanced TumorsRecruitingNCT06683846Phase 2
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- Institutional Registry of Rare DiseasesRecruitingNCT06573723
- Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsRecruitingNCT06523582
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitingNCT06479811Phase 1
- Hereditary Pheochromocytoma Assessment of Tumour ImmunologiesRecruitingNCT06444607
- The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)RecruitingNCT06440122
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand TherapyRecruitingNCT06427798Phase 1/2
- Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemRecruitingNCT06377033Not applicable
- Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine GreenRecruitingNCT06155734
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCRecruitingNCT06045260Phase 2
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 1
- The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingNCT05885399Phase 2
- A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGLRecruitingNCT05885386Phase 2
- Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma ResectionRecruitingNCT05752773
- The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive PheochromocytomaRecruitingNCT05702944Phase 4
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsRecruitingNCT05636618Phase 1/2
- In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and ParagangliomaRecruitingNCT05636540Early Phase 1
- Exendin PET/CT for Imaging of ParagangliomasRecruitingNCT05418907
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingNCT05069220Early Phase 1
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Phase 2
- Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort StudyNot yet recruitingNCT04788927
- In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- ParagangliomasRecruitingNCT04583384Not applicable
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 1
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.RecruitingNCT04081701Phase 4
- Multicenter Pheochromocytoma and Paraganglioma EvaluationRecruitingNCT03344016Not applicable
- Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaRecruitingNCT03206060Phase 2
- Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated ConditionsRecruitingNCT03160274
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
- Expanded Access Protocol Using 131I-MIBGAvailableNCT01590680
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruitingNCT04711135Phase 2Results posted
- Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/2Results posted
- Preoperative Alpha Blockade for PheochromocytomaCompletedNCT03176693Phase 3Results posted
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
- Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by SurgeryCompletedNCT03008369Phase 2Results posted
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted
- Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by SurgeryCompletedNCT02302833Phase 2Results posted
- GA-68 DOTA-TOC of Somatostatin Positive MalignanciesTerminatedNCT02177773Phase 1/2Results posted
- Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompletedNCT01967576Phase 2Results posted
- Linsitinib in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT01560260Phase 2Results posted
- A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related TumorsCompletedNCT01413503Phase 2Results posted
- Stereotactic Body Radiotherapy for Spine TumorsCompletedNCT01347307Not applicableResults posted
- Stereotactic Body Radiotherapy for Head and Neck TumorsCompletedNCT01344356Phase 4Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or ParagangliomaTerminatedNCT01340794Phase 2Results posted
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaStatus unknownNCT00874614Phase 2Results posted
- Study Of Sunitinib In Patients With Recurrent Paraganglioma/PheochromocytomaCompletedNCT00843037Phase 2Results posted
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedNCT00458952Phase 1/2Results posted
- The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）CompletedNCT07412158
- Correlation Between Preoperative Images of PPGL and Intraoperative HemodynamicsCompletedNCT06669481
- 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemWithdrawnNCT06233903Phase 2
- F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and ParagangliomaTerminatedNCT05948137
- Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in TurkeyCompletedNCT05942482
- A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGLStatus unknownNCT05883085Phase 2
- The Efficacy and Safety of Temozolomide in Patients With MPPGLCompletedNCT05858177Phase 2
- Predictors and Outcomes of Dysglycemia in Pheochromocytoma and ParagangliomaStatus unknownNCT05451134
- Prognostic's Factors of Head and Neck Paragangliomas EvolutionActive, not recruitingNCT05233878
- A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory TrialStatus unknownNCT05133349Phase 2
- Cardiac and Vascular Changes in Pheochromocytoma and ParagangliomaCompletedNCT05082311
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
- Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart DiseaseStatus unknownNCT04891081
- The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or ParagangliomaCompletedNCT04860700Phase 2
- Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)TerminatedNCT04605848Not applicable
- Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or ParagangliomaCompletedNCT04573816
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
- Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
- Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingStatus unknownNCT04017104
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)Active, not recruitingNCT03946527Phase 2
- Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and AdolescentsWithdrawnNCT03923257Phase 1/2
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/ParagangliomaActive, not recruitingNCT03839498Phase 2
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaApproved for marketingNCT02961491
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
- Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas EvaluationCompletedNCT02186678Not applicable
- Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and ParagangliomaWithdrawnNCT01941849Phase 1
- Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or ParagangliomaNo longer availableNCT01838187
- Dovitinib in Neuroendocrine TumorsCompletedNCT01635907Phase 2
- Compassionate Use of 131I-MIBG for Patients With Malignant PheochromocytomaApproved for marketingNCT01377532
- 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsStatus unknownNCT01373736Phase 3
- First International Randomized Study in Malignant Progressive Pheochromocytoma and ParagangliomaCompletedNCT01371201Phase 2